Technical Analysis for AERI - Aerie Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical AERI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.81% | |
| 20 DMA Resistance | Bearish | -2.96% | |
| Fell Below 50 DMA | Bearish | -2.96% | |
| Fell Below 20 DMA | Bearish | -5.18% | |
| MACD Bearish Centerline Cross | Bearish | -5.18% | |
| 50 DMA Support | Bullish | -6.81% | |
| Crossed Above 20 DMA | Bullish | -6.81% | |
| MACD Bullish Centerline Cross | Bullish | -6.81% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 2 % | about 17 hours ago |
| Down 1% | about 18 hours ago |
| Fell Below Previous Day's Low | about 18 hours ago |
| Trending on StockTwits | about 21 hours ago |
| Down 3% | 4 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/25/2021
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its product candidates include dual-action AR-13324, a once-daily eye drop to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, which has completed a Phase IIb clinical trials; triple-action PG324, a single drop fixed-dose combination of AR-13324 and latanoprost for the treatment of patients with glaucoma; and AR-13533, a dual-action ROCK/NET inhibitor that is in preclinical development stage. The company was founded in 2005 and is headquartered in Bedminster, New Jersey.
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Pharmaceutical Diseases Clinical Development Eye Chemical Compounds Organic Compounds Hypertension Stage Pharmaceutical Alcohols Glaucoma Cyclopropanes Bedminster Intraocular Pressure Ocular Hypertension Prostaglandins
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Pharmaceutical Diseases Clinical Development Eye Chemical Compounds Organic Compounds Hypertension Stage Pharmaceutical Alcohols Glaucoma Cyclopropanes Bedminster Intraocular Pressure Ocular Hypertension Prostaglandins
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.3 |
| 52 Week Low | 9.01 |
| Average Volume | 560,271 |
| 200-Day Moving Average | 14.05 |
| 50-Day Moving Average | 18.22 |
| 20-Day Moving Average | 18.14 |
| 10-Day Moving Average | 18.12 |
| Average True Range | 1.04 |
| ADX | 21.73 |
| +DI | 14.32 |
| -DI | 26.36 |
| Chandelier Exit (Long, 3 ATRs ) | 17.30 |
| Chandelier Exit (Short, 3 ATRs ) | 19.53 |
| Upper Bollinger Band | 19.39 |
| Lower Bollinger Band | 16.88 |
| Percent B (%b) | 0.2 |
| BandWidth | 13.84 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.06 |
| MACD Histogram | -0.1211 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.14 | ||||
| Resistance 3 (R3) | 18.06 | 17.73 | 18.02 | ||
| Resistance 2 (R2) | 17.73 | 17.54 | 17.77 | 17.97 | |
| Resistance 1 (R1) | 17.56 | 17.42 | 17.65 | 17.64 | 17.93 |
| Pivot Point | 17.23 | 17.23 | 17.27 | 17.27 | 17.23 |
| Support 1 (S1) | 17.06 | 17.04 | 17.15 | 17.14 | 16.85 |
| Support 2 (S2) | 16.73 | 16.92 | 16.77 | 16.81 | |
| Support 3 (S3) | 16.56 | 16.73 | 16.77 | ||
| Support 4 (S4) | 16.64 |
